912259-11-1

Basic information

• Product Name: 6,6-dimethyl-6,7-dihydro-1H-indazol-4(5H)-one
• Synonyms: 6,6-dimethyl-6,7-dihydro-1H-indazol-4(5H)-one;6,6-Dimethyl-1,5,6,7-tetrahydro-indazol-4-one
• CAS NO: 912259-11-1
• Molecular Formula: C₉H₁₂N₂O
• Molecular Weight: 164.20438
• Mol File: 912259-11-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6,6-dimethyl-6,7-dihydro-1H-indazol-4(5H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6,6-dimethyl-6,7-dihydro-1H-indazol-4(5H)-one(912259-11-1)
• EPA Substance Registry System: 6,6-dimethyl-6,7-dihydro-1H-indazol-4(5H)-one(912259-11-1)

Safety Data

• Hazardous Substances Data: 912259-11-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6,6-Dimethyl-6,7-dihydro-1H-indazol-4(5H)-one is used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties make it an important building block in drug discovery, particularly for the development of CNS drugs.
Used in Drug Discovery:
6,6-Dimethyl-6,7-dihydro-1H-indazol-4(5H)-one is used as a potential building block in drug discovery, with potential applications in the treatment of various diseases and medical conditions. Its unique structure and properties make it a valuable compound for the development of new therapeutic agents.

Upstream product

• 75039-59-7 2-dimethylaminomethylene-5,5-dimethylcyclohexane-1,3-dione 
• 126-81-8 dimedone 

Downstream Products

• 596845-57-7 6,6-dimethyl-2-trityl-2,5,6,7-tetrahydro-indazol-4-one 
• 1355248-91-7 C₁₇H₂₀N₂O₂ 
• 1355248-92-8 C₁₇H₂₀N₂O₂ 
• 1355248-93-9 C₁₇H₁₉BrN₂O₂ 

Relevant articles and documents

Novel crown ether functionalized imidazolium-based acidic ionic liquid catalyzed synthesis of pyrazole derivatives under solvent-free conditions

Abstract An innovatively designed novel crown ether functionalized imidazolium-based reusable acidic ionic liquid [crown ether MIm] [HSO4] has been efficiently implemented for the synthesis of pyrazole derivatives using various substituted enaminones, hydrazine hydrate and phenyl hydrazine under solvent-free conditions. Structural novelty and task efficiency of the catalyst, high yields of desired products, greener approach attributing high atom economy and solvent-free conditions render this protocol suitable to cope with the current demand in contemporary organic chemistry. The inventive idea of utilizing crown ether functionalized ionic liquid as a catalyst was for the first time demonstrated in this protocol.

TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention describes and claims compounds of the Structural Formula (I), Structural Formula (II), or Structural Formula (III). In Formula (I), R1, R2, R3 and R3' are -H or methyl, or R3 and R3' taken together form a double bond, or R3' is -H and R2 and R3 taken together form a spiro-cyclopropyl substituent, R4 is -H or -F, and R5 is -H, methyl, -Cl or -Br. In Formula (II), R1 is -H, ethyl-, isopropyl-, cyclopropyl-, methyl- or methoxy-, R4 is -H or -F, and "Y" is: (a) -CH2-; (b) -CR6H-O-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (c) -CR6H-N(R9)-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (d) -CH2-C(R9)(R10)-C(R7)(R8)-, wherein R7, R8, R9 and R10 are independently -H or -methyl, or both R7 and R8 are -F, R9 and R10 are independently -H or -methyl, or both R9 and R10 are -F, or R9 and R10 taken together are (O=), which together with the carbon to which they are attached forms a carbonyl group.

TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention describes and claims compounds of the Structural Formula I, Structural Formula II, or Structural Formula III: wherein R1, R2, R3 and R3' are -H or methyl, or R3 and R3 taken together form a double bond, or R3' is -H and R2 and R3 taken together form a spiro-cyclopropyl substituent, R4 is -H or -F, and R5 is -H, methyl, -CI or -Br, Formula II wherein R1 is -H, ethyl-, isopropyl-, cyclopropyl-, methyl- or methoxy-, R4 is -H or -F, and "Y" is: (a) -CH2-; (b) -CR6H-0-CR7R8-, wherein R6, R7, and R8 are independently - H or methyl; (c) -CR6H-N(R9)-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (d) -CH2-C(R9)(R10)-C(R7)(R8)-, wherein R7, R8, R9 and R10 are independently - H or -methyl, or both R7 and R8 are -F, R9 and R10 are independently -H or -methyl, or both R9 and R10 are -F, or R9 and R10 taken together are (0=), which together with the carbon to which they are attached forms a carbonyl group.

HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of Formula (I), wherein wherein X1, X2, Y, Z1, Z2, Z3, M and (A)m are defined as in Formula (I); invention compounds are modulators of metab

Synthesis and structural study of tetrahydroindazolones

Multinuclear magnetic resonance spectroscopy allowed us to characterize four 1(2),5,6,7-tetrahydro-4H-indazol-4-one derivatives (1-4) and establish the most stable tautomer in each case. The crystal structure of 6,6-dimethyl-1(2),5,6,7-tetrahydro-4H-indaz

Benzodipyrazoles: A new class of potent CDK2 inhibitors

The synthesis and the preliminary expansion of this new class of CDK2 inhibitors are presented. The synthesis was accomplished using a solution-phase protocol amenable to rapid parallel expansion and suitable to be scaled-up in view of possible lead devel

A Novel Amino Protection-Deprotection Procedure and Its Application in Solid Phase Peptide Synthesis

N-4,4-Dimethyl-2,6-dioxocyclohexylidenemethyl (Dcm) amino acids are readily prepared and the protecting group can be removed with hydrazine at room temperature; their potential in solid phase peptide synthesis is illustrated.